1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer/Tumor Profiling Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
5.1.1.2. Availability of government and global organizations’ initiatives for devising cancer diagnosing methods
5.1.1.3. Surging preference for personalized medicines for cancer treatment
5.1.2. Restraints
5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
5.1.3. Opportunities
5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
5.1.4. Challenges
5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Market Segmentation Analysis
5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
5.3. Market Trend Analysis
5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Cancer/Tumor Profiling Market, by Technology
6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Polymerase Chain Reaction
7. Cancer/Tumor Profiling Market, by Biomarker Type
7.1. Introduction
7.2. Genomic Biomarker
7.3. Protein Biomarker
8. Cancer/Tumor Profiling Market, by Cancer Type
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma Cancer
8.6. Prostate Cancer
9. Cancer/Tumor Profiling Market, by Application
9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring
10. Americas Cancer/Tumor Profiling Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer/Tumor Profiling Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
13.3.1.2. Prenetics Acquires ACT Genomics
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore’s Genomic Profiling on Asian-prevalent Cancers
13.3.2.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
13.3.2.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
13.3.3. New Product Launch & Enhancement
13.3.3.1. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
13.3.3.2. ​​Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
13.3.4. Investment & Funding
13.3.4.1. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
13.3.4.2. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
13.3.5.2. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. 4basecare Onco Solutions Private Limited
14.1.2. ACT Genomics Co., Ltd. by Prenetics Global Limited
14.1.3. Agendia, Inc.
14.1.4. Agilent Technologies, Inc.
14.1.5. BostonGene Corporation
14.1.6. Caris Life Sciences
14.1.7. Exact Sciences Corporation
14.1.8. F. Hoffmann-La Roche Ltd.
14.1.9. GENINUS Inc.
14.1.10. Genomic Life
14.1.11. GenScript Biotech Corporation
14.1.12. Guardant Health, Inc.
14.1.13. Hologic, Inc.
14.1.14. HTG Molecular Diagnostics, Inc.
14.1.15. Illumina, Inc.
14.1.16. IMBdx, Inc.
14.1.17. Laboratory Corporation of America Holdings
14.1.18. Lucence Health, Inc.
14.1.19. Merck KGaA
14.1.20. NanoString Technologies, Inc.
14.1.21. Neogenomics, Inc.
14.1.22. Nonacus Limited
14.1.23. OncoDNA S.A.
14.1.24. Oncompass Medicine Hungary Kft.
14.1.25. Paragon Genomics, Inc.
14.1.26. Personalis, Inc.
14.1.27. Perthera, Inc.
14.1.28. Predictive Oncology Inc.
14.1.29. Strand Life Sciences
14.1.30. Sysmex Corporation
14.1.31. Takara Bio Inc.
14.1.32. Tempus Labs Inc.
14.1.33. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing